FDA has published the proposed new rule, Annual Summary Reporting Requirements under the Right to Try Act, that, when finalized, will implement a statutory requirement for sponsors and manufacturers to provide an annual summary to the FDA for any eligible investigational drug they provide to eligible patients under the Right to Try Act. jQuery(document).ready(function(){ jQuery('.people-thumb...
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
